Its on-target toxicity of thrombocytopenia induced by Bcl-xL inhibition prevents its use in clinic even for tumor patients (Gandhi et al., 2011; Souers et al., 2013; Leverson et al., 2015; Ashkenazi et al., 2017). Here, BCL2L1 is linked to neoplasm.